Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels
- PMID: 1793438
- DOI: 10.1016/0021-9150(91)90050-d
Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels
Abstract
The risk of premature coronary artery disease is related to an important degree to the number of particles of low density lipoproteins (LDL) in plasma, an estimate given by measurement of LDL apo B. In clinical practise, though it is total, not LDL apo B, which is measured. The purpose of the present study therefore was to compare plasma total and LDL apo B in the presence and absence of moderate hypertriglyceridemia. The results demonstrate that within the range of plasma triglyceride levels examined, i.e., values of triglyceride up to 500 mg/dl, there is close correspondence between total and LDL apo B, with the latter more than 90% of the former. VLDL composition was also examined and two patterns found in hypertriglyceridemic patients: those with normal apo B had markedly lipid enriched VLDL while those with elevated apo B had VLDL which was normal in composition except for a moderate increase in triglyceride content. Thus total apo B within the circumstances studied reflects principally LDL apo B. Moreover measurement of apo B allows distinction between two different forms of hypertriglyceridemia, only one of which - that with an increased LDL particle number - has previous work shown to be associated with increased coronary risk. Total apo B, therefore, provides additional information not available from conventional plasma and lipoprotein lipids which allows more precise physiologic classification and may lead to more rational choice of pharmacologic therapy in normolipidemic and hypertriglyceridemic patients.
Similar articles
-
Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.J Clin Invest. 1985 Feb;75(2):614-23. doi: 10.1172/JCI111739. J Clin Invest. 1985. PMID: 3973021 Free PMC article.
-
An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men, independently of intermediate-density lipoprotein or low-density lipoprotein.Coron Artery Dis. 2002 Aug;13(5):255-62. doi: 10.1097/00019501-200208000-00002. Coron Artery Dis. 2002. PMID: 12394649
-
Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.Biochim Biophys Acta. 2000 Feb 24;1484(1):29-40. doi: 10.1016/s1388-1981(99)00197-3. Biochim Biophys Acta. 2000. PMID: 10685028
-
How, when, and why to use apolipoprotein B in clinical practice.Am J Cardiol. 2002 Oct 17;90(8A):48i-54i. doi: 10.1016/s0002-9149(02)02633-4. Am J Cardiol. 2002. PMID: 12419480 Review.
-
In vivo studies of VLDL metabolism and LDL heterogeneity.Eur Heart J. 1998 Jul;19 Suppl H:H7-10. Eur Heart J. 1998. PMID: 9717058 Review.
Cited by
-
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.Nat Rev Endocrinol. 2010 Jun;6(6):335-46. doi: 10.1038/nrendo.2010.50. Epub 2010 Apr 27. Nat Rev Endocrinol. 2010. PMID: 20421882 Review.
-
Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):404-11. doi: 10.1161/ATVBAHA.115.306268. Epub 2015 Dec 17. Arterioscler Thromb Vasc Biol. 2016. PMID: 26681752 Free PMC article. Clinical Trial.
-
Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.Curr Cardiol Rep. 2009 Nov;11(6):468-75. doi: 10.1007/s11886-009-0067-z. Curr Cardiol Rep. 2009. PMID: 19863872 Review.
-
LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.J Clin Lipidol. 2007 Dec;1(6):583-92. doi: 10.1016/j.jacl.2007.10.001. J Clin Lipidol. 2007. PMID: 19657464 Free PMC article.
-
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.Vasc Health Risk Manag. 2010 Nov 24;6:1065-75. doi: 10.2147/VHRM.S14053. Vasc Health Risk Manag. 2010. PMID: 21191426 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical